Artrya Secures US$950 Per Scan Reimbursement for Salix Coronary Plaque Module
Artrya Limited has begun generating fee-per-scan revenues from its Salix Coronary Plaque module at Tanner Health in the U.S., marking a key commercial milestone for the AI-powered cardiac imaging platform.
- First fee-per-scan revenues from Salix Coronary Plaque module initiated
- Tanner Health expands use of Salix platform across its workflow
- U.S. reimbursement rate set at US$950 per scan assessment
- Five-year commercial agreement underpins ongoing revenue streams
- Rollout to additional Tanner Health hospitals planned soon
A Milestone in AI-Driven Cardiac Care
Artrya Limited (ASX, AYA), an Australian medical technology innovator, has announced the commencement of fee-per-scan revenues from its Salix Coronary Plaque module at Tanner Health, a foundational U.S. customer. This development represents a significant commercial step for Artrya’s AI-powered platform designed to enhance the diagnosis and management of coronary artery disease.
The Salix platform, which analyses coronary CT scans to identify critical biomarkers of heart disease, has been integrated into Tanner Health’s workflow since a five-year commercial agreement was signed in July 2025. Initially subscribing to the Salix Coronary Anatomy software, Tanner Health has now expanded its use to include the FDA-cleared Coronary Plaque module, enabling more detailed assessments.
Revenue Model and Market Opportunity
Under the terms of the agreement, Artrya receives both subscription fees and fee-per-scan payments. The latter is supported by a U.S. Category 1 CPT reimbursement code, which allows Tanner Health to claim approximately US$950 for each scan assessed using the Salix Coronary Plaque module. This reimbursement framework not only validates the clinical value of the technology but also opens a lucrative revenue stream for Artrya.
The initial rollout has begun at Tanner Health’s primary hospital in Carrollton, Georgia, with plans to extend the module’s use across additional hospitals within the Tanner network. The integration process was facilitated by Artrya’s newly established U.S. Customer Support team, which provided comprehensive training and assistance with billing and reimbursement coding.
Strategic Implications and Future Outlook
John Konstantopoulos, Artrya’s CEO, expressed enthusiasm about the milestone, highlighting the smooth activation and positive reception by clinicians. The company anticipates that broader adoption within Tanner Health will generate a steady and attractive revenue stream from each scan assessed.
From Tanner Health’s perspective, the Salix Coronary Plaque module offers tangible benefits by enabling faster, more accurate assessments of coronary artery disease, which can improve patient outcomes. Dr. Shazib Khawaja, Chair of Heart and Vascular Services at Tanner Health, noted the ease of integration and the value of having a single system for comprehensive cardiac imaging analysis.
Looking ahead, Artrya’s success with Tanner Health could serve as a blueprint for expanding its footprint across other U.S. health systems and international markets. The combination of AI-driven technology, regulatory clearance, and established reimbursement pathways positions Artrya well in the competitive medical imaging landscape.
Bottom Line?
Artrya’s first fee-per-scan revenues mark a promising start, but scaling adoption and sustaining reimbursement will be key to unlocking its full commercial potential.
Questions in the middle?
- How quickly will Tanner Health expand the Salix Plaque module across its network?
- Can Artrya replicate this commercial success with other U.S. health systems?
- Will reimbursement rates remain stable amid evolving healthcare policies?
